{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:29Z","timestamp":1793212109515,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cgh.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:50:49Z","timestamp":1772178649000},"page":"2783-2795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2\/3 Studies"],"prefix":"10.1016","volume":"24","author":[{"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Klaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Suravaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Vladea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saajan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I.","family":"Anyanwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.02.018_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.018_bib2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.02.018_bib3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2026.02.018_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474124.2023.2172399","article-title":"A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis","volume":"17","author":"Law","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.cgh.2026.02.018_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2026.02.018_bib10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2026.02.018_bib11","first-page":"i1821","article-title":"P1008 efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: data from the phase 3 open-label extension study U-ACTIVATE","volume":"18","author":"Panaccione","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib13","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.02.018_bib14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib15","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ibd\/izaf115","article-title":"Incidence and risk factors for development of acne (JAKne) in patients with inflammatory bowel disease treated with upadacitinib","volume":"31","author":"Choi","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.02.018_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.02.018_bib17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cgh.2025.04.031","article-title":"Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease: an international, multicenter, retrospective cohort study","volume":"24","author":"Honap","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib18","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2025.06.041","article-title":"Comparative safety of Janus kinase inhibitors vs tumor necrosis factor antagonists in patients with inflammatory bowel diseases","volume":"24","author":"Ahuja","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib19","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"26","author":"Cheng","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.02.018_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf198","article-title":"Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b\/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease","volume":"20","author":"Vermeire","year":"2026","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.02.018_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001392","article-title":"Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study","volume":"6","author":"Galloway","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2026.02.018_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","article-title":"Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance","volume":"20","author":"Danese","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.02.018_bib23","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:42:32Z","timestamp":1790066552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652600145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S154235652600145X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.02.018","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2\/3 Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}